Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2007

View Archived Issues

Transient improvement in rheumatoid arthritis activity seen with CRx-139

Kiadis to provide Rhitol to physicians participating in phase I/II trial closed for enrollment

Artemisinin derivative shows promise in models of autoimmune inflammatory disease

Recent patents disclose new therapeutic options for neuropsychiatric disorders

New therapeutic agents for endocrine disorders disclosed in recent patents

Ardana reports positive preliminary results from phase II study of teverelix LA

Novel agents for allergic and respiratory disorders described in recent Boehringer Ingelheim patent

Preclinical studies of arthritis therapy target TNF-alpha and Bcl-2

Selective and multitargeted B-Raf inhibitors described at Deciphera

Selective LMP7 proteasome inhibitor shows antirheumatic activity in vivo

P2X7 receptor blockade is associated with reduced joint destruction in inflammatory arthritis

Modulation of 5-HT2 signaling shows benefit in models of inflammatory arthritis

European Commission approves Wyeth Pharmaceuticals' Torisel for renal cell carcinoma

MedImmune initiates phase I clinical trial of CAM-3001 for rheumatoid arthritis

Roche and Maxygen terminate development of MAXY-alpha

Merck & Co. files marketing authorization application with EMEA for vorinostat

LEO Pharma launches ATryn for hereditary antithrombin deficiency

FDA removes hold on Targeted Genetics' phase I/II clinical trial of tgAAC-94

Sygnis and Dr. Reddy's enter 10-year supply agreement for AX-200 for stroke

Daval International gets MHRA approval for phase IIb trial of Aimspro for MS

Mercury develops protein-kinase technology for treatment of type 2 diabetes

VioQuest initiates phase IIa study of Lenocta for the treatment of solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...